История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B | $2.1B | $2.2B | $2.2B | $2.1B | $1.9B | $1.7B | $1.6B | $2.0B | $1.8B | $1.5B |
| Валовая прибыль | $1.5B | $1.5B | $1.3B | $1.3B | $1.8B | $2.3B | $2.0B | $1.3B | $1.3B | $1.0B | $972M | $930M | $971M | $940M | $924M | $824M | $740M | $699M | $835M | $715M | $623M |
| Валовая маржа % | 52.1% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% | 44.2% | 43.4% | 43.4% | 43.7% | 42.9% | 43.4% | 45.1% | 42.6% | 40.0% | 40.3% |
| Операционная прибыль (EBIT) | $358M | $357M | $411M | $399M | $781M | $1.3B | $1.0B | $405M | $371M | $305M | $306M | $267M | $230M | $259M | $201M | $118M | $173M | $140M | $201M | $175M | $152M |
| Операционная маржа % | 12.3% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% | 12.7% | 10.3% | 11.9% | 9.5% | 6.1% | 10.1% | 9.0% | 10.3% | 9.8% | 9.8% |
| Чистая прибыль | $238M | $242M | $296M | ($118M) | $569M | $943M | $728M | $228M | $239M | $113M | $234M | $212M | $158M | $168M | $68M | $1M | $384M | $86M | $128M | $133M | $117M |
| Чистая маржа % | 8.2% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.1% | 10.1% | 7.1% | 7.8% | 3.2% | 0.1% | 22.5% | 5.5% | 6.6% | 7.4% | 7.6% |
| EBITDA | — | $663M | $840M | $714M | $1.2B | $1.6B | $1.2B | $515M | $505M | $446M | $386M | $352M | $323M | $332M | $223M | $200M | $267M | $201M | $263M | $245M | $229M |
| Прибыль на акцию (EPS) | $2.09 | $2.13 | $2.41 | $-0.95 | $4.50 | $8.08 | $6.50 | $2.04 | $2.14 | $1.02 | $2.12 | $1.87 | $1.39 | $1.48 | $0.60 | $0.01 | $3.25 | $0.73 | $1.08 | $1.10 | $0.93 |
| Акции в обращении (M) | — | 113M | 123M | 125M | 126M | 117M | 112M | 112M | 112M | 111M | 110M | 113M | 114M | 114M | 115M | 114M | 118M | 117M | 119M | 121M | 126M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике RVTY. /companies/us/RVTY
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms